Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.47 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14931850 | 1.00 | GRM2 (0.47) | GRM2GRM3SMN1; SMN2TSHRKDM4E | |
| SCHEMBL233581 | 0.91 | GRM2 (0.48) | GRM2GRM3SMN1; SMN2TSHRKDM4E | |
| SCHEMBL231932 | 0.81 | GRM2 (0.42) | GRM2GRM3TSHR | |
| SCHEMBL514523 | 0.80 | GRM2 (0.70) | GRM2GRM3 | |
| SCHEMBL4967900 | 0.80 | GRM2 (0.70) | GRM2GRM3 | |
| SCHEMBL4967909 | 0.80 | GRM2 (0.70) | GRM2GRM3 | |
| SCHEMBL232413 | 0.79 | GRM2 (0.48) | GRM2GRM3SMN1; SMN2TSHRKDM4E | |
| SCHEMBL233390 | 0.79 | GRM2 (0.48) | GRM2GRM3SMN1; SMN2TSHRKDM4E | |
| SCHEMBL14931849 | 0.79 | GRM2 (0.48) | GRM2GRM3SMN1; SMN2TSHRKDM4E | |
| SCHEMBL232799 | 0.79 | GRM2 (0.48) | GRM2GRM3SMN1; SMN2TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8350060-B2 | 2-amino-bicyclo[3.1.0] hexane-2, 6-dicarboxylic ester derivative | Taisho Pharamceutical Co., Ltd. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-8258133-B2 | 2-amino-bicyclo[3.1.0]hexane-2, 6-dicarboxylic ester derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-09-04 | — | — | US | disclosed |
| US-20120028982-A1 | 2-AMINO-BICYCLO[3.1.0]HEXANE-2, 6-DICARBOXYLIC ESTER DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| US-20120004232-A1 | 2-AMINO-BICYCLO(3.1.0) HEXANE-2, 6-DICARBOXYLIC ESTER DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-05 | — | — | US | disclosed |
| US-8076502-B2 | 2-amino-bicyclo(3.1.0) hexane-2,6-dicarboxylic ester derivative | TAISHO PHARMACEUTICALS CO., LTD. (JP) | 2011-12-13 | — | — | US | disclosed |
| US-8039647-B2 | 2-amino-bicyclo (3.1.0) hexane-2,6-dicarboxylic ester derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
| US-7960579-B2 | 2-amino-bicyclo [3.1.0] hexane-2,6-dicarboxylic ester derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| EP-2287147-A2 | 2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-02-23 | — | — | EP | disclosed |
| US-20100298561-A1 | 2-AMINO-BICYCLO(3.1.0) HEXANE-2, 6-DICARBOXYLIC ESTER DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-11-25 | — | — | US | disclosed |
| EP-1637517-B1 | 2-AMINOBICYCLO 3.1.0 HEXANE-2,6-DICARBOXYLIC ESTER DERIVATIVE | TAISHO PHARMACEUTICAL CO LTD (JP) | 2010-11-10 | — | — | EP | disclosed |
| US-20090306408-A1 | 2-Amino-Bicyclo (3.1.0) Hexane-2,6-Dicarboxylic Ester Derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| US-20070021394-A1 | 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-25 | — | — | US | disclosed |
| EP-1637517-A1 | 2-AMINOBICYCLO 3.1.0 HEXANE-2,6-DICARBOXYLIC ESTER DERIVATIVE | Taisho Pharmaceutical Co. Ltd. (JP) | 2006-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306408-A1 | 2-Amino-Bicyclo (3.1.0) Hexane-2,6-Dicarboxylic Ester Derivative | GRIK4, GRIN2D, GRIN2C | GRM2 7/4885GRM3 23/4885SMN1; SMN2 3603/4885 |
| US-20070021394-A1 | 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative | GRIN2C, GRIK4, GRIN2B | GRM2 13/4885GRM3 10/4885SMN1; SMN2 3707/4885 |
| US-20120028982-A1 | 2-AMINO-BICYCLO[3.1.0]HEXANE-2, 6-DICARBOXYLIC ESTER DERIVATIVE | GRIK4, GRIN2D, GRIN2C | GRM2 6/4885GRM3 23/4885SMN1; SMN2 3594/4885 |
| US-20100298561-A1 | 2-AMINO-BICYCLO(3.1.0) HEXANE-2, 6-DICARBOXYLIC ESTER DERIVATIVE | GRIK4, GRIN2D, GRIN2C | GRM2 7/4885GRM3 23/4885SMN1; SMN2 3603/4885 |
| US-20120004232-A1 | 2-AMINO-BICYCLO(3.1.0) HEXANE-2, 6-DICARBOXYLIC ESTER DERIVATIVE | GRIK4, GRIN2D, GRIN2C | GRM2 7/4885GRM3 23/4885SMN1; SMN2 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.